详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

1| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

参与国家：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究单位： [1]Hoffmann-La Roche [2]Chugai Pharmaceutical Co. [3]University of Alabama at Birmingham,Birmingham,Alabama,United States,35233 [4]Instytut Psychiatrii I Neurologii II Klinika Neurologiczna,Warszawa,Poland,02-957 [5]University of Colorado [6]Anschutz Medical Campus Department of Neurology,Aurora,Colorado,United States,80045 [7]University Hospitals of Cleveland,Cleveland,Ohio,United States,44106 [8]Swedish Neuroscience Institute,Seattle,Washington,United States,98122 [9]Hospital Britanico,Ciudad Autonoma Bs As,Argentina,C1280AEB [10]Sanatorio del Sur S.A.,San Miguel de Tucuman,Argentina,T4000IDK [11]Beijing Tongren Hospital,Beijing,China,100730 [12]Fakultni nemocnice v Motole [13]Neurologicka klinika 2. LF UK a FN Motol,Praha 5,Czechia,150 06 [14]Irccs A.O.U.San Martino Ist [15]Dinogmi,Genova,Liguria,Italy,16132 [16]IRCCS Ospedale San Raffaele [17]Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla,Milano,Lombardia,Italy,20132 [18]Fondazione IRCCS Istituto Neurologico Carlo Besta,Milano,Lombardia,Italy,20133 [19]Fukuoka University Hospital,Fukuoka,Japan,814-0180 [20]Gifu University Hospital,Gifu,Japan,501-1194 [21]Hokkaido University Hospital,Hokkaido,Japan,060-8648 [22]St.Marianna University School of Medicine hospital [23]Medical Oncology,Kanagawa,Japan,216-8511 [24]Kitasato University Hospital,Kanagawa,Japan,252-0375 [25]Tohoku University Hospital,Miyagi,Japan,980-8574 [26]Kinki University Hospital, Faculty of Medicine,Osaka-sayama,Japan,589-8511 [27]Nihon University Itabashi Hospital,Tokyo,Japan,173-8610 [28]Seoul National University Hospital,Seoul,Korea, Republic of,03080

研究目的：

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.